JJKK 048 inhibits monoacylglycerol lipase by terminating signaling pathway of 2-arachidonoylglycerol in mouse brain and human melanoma cell proteome. JJKK 048 can be classified as a MAGL inhibitor that has therapeutic potential for the treatment of cancers.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.